Clinical Trials
33 trialsStudying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
NEO-IMPACT
Australasian Gastro-Intestinal Trials Group
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
PaTcH
Cancer Trials Ireland
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Proton Collaborative Group
FEED
Cancer Trials Ireland
ASCEND
Australasian Gastro-Intestinal Trials Group
OligoRARE
European Organisation for Research and Treatment of Cancer - EORTC
PRIORITY-CONNECT 2 Pilot Trial
Surgical Outcomes Research Centre (SOuRCe)
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Canadian Cancer Trials Group
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
Eastern Cooperative Oncology Group
Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Eastern Cooperative Oncology Group
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Eastern Cooperative Oncology Group
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Canadian Cancer Trials Group
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
Canadian Cancer Trials Group
High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
SWOG Cancer Research Network
S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer
SWOG Cancer Research Network
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas
Radiation Therapy Oncology Group
Net-Pac
CHIR-Net
Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer
Cancer Trials Ireland
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Radiation Therapy Oncology Group
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
Radiation Therapy Oncology Group
Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Radiation Therapy Oncology Group
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
SWOG Cancer Research Network
Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
European Organisation for Research and Treatment of Cancer - EORTC
GIP-1
Istituti Tumori Giovanni Paolo II